A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice

Biochemical and Biophysical Research Communications

Volumn 450, Issue 1, 2014, Pages 532-537

  Tomioka, Yukiko ^a,b   Morimatsu, Masami ^a,c   Nishijima, Ken Ichi ^d   Usui, Tatsufumi ^b   Yamamoto, Sayo ^e   Suyama, Haruka ^e   Ozaki, Kinuyo ^e   Ito, Toshihiro ^b   Ono, Etsuro ^b,e  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

Antitumor benefit; Mammary tumor; MUC1; Soluble Siglec 9; Transgenic mice

Indexed keywords

CD33 ANTIGEN; CYCLINE; MUCIN 1; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIGLEC 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES TUMOR; BREAST TUMOR; CELL AGGREGATION; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR GROWTH;

MUS MUSCULUS;

ANTITUMOR BENEFIT; MAMMARY TUMOR; MUC1; SOLUBLE SIGLEC-9; TRANSGENIC MICE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCIN-1; SOLUBILITY;

EID: 84904736550     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.06.009     Document Type: Article

References (31)

1. D. Kufe, G. Inghirami, and M. Abe et al. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors Hybridoma 3 1984 223 232
2. J. Wesseling, S.W. van der Valk, and H.L. Vos et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components J. Cell Biol. 129 1995 255 265
3. M.J. Ligtenberg, L. Kruijshaar, and F. Buijs et al. Cell-associated episialin is a complex containing two proteins derived from a common precursor J. Biol. Chem. 267 1992 6171 6177
4. F. Levitin, A. Baruch, and M. Weiss et al. A novel protein derived from the MUC1 gene by alternative splicing and frameshifting J. Biol. Chem. 280 2005 10655 10663
5. B. Macao, D.G.A. Johansson, and G.C. Hansson et al. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin Nat. Struct. Mol. Biol. 13 2006 71 76
6. E.A. Rakha, R.W.G. Boyce, and D. Abd El-Rehim et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer Mod. Pathol. 18 2005 1295 1304
7. J.J. Rahn, L. Dabbagh, and M. Pasdar et al. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature Cancer 91 2001 1973 1982
8. M.A. McGuckin, M.D. Walsh, and B.G. Hohn et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer Hum. Pathol. 26 1995 432 439
9. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat. Rev. Cancer 9 2009 874 885
10. S. Yonezawa, M. Goto, and N. Yamada et al. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior Proteomics 8 2008 3329 3341
11. D. Raina, S. Kharbanda, and D. Kufe The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts J. Biol. Chem. 279 2004 20607 20612
12. L. Yin, L. Huang, and D. Kufe MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress J. Biol. Chem. 279 2004 45721 45727
13. X. Wei, H. Xu, and D. Kufe Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response Cancer Cell 7 2005 167 178
14. D.W. Kufe MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches Oncogene 32 2013 1073 1081
15. L. Huang, D. Chen, and D. Liu et al. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin Cancer Res. 65 2005 10413 10422
16. M.D. Pegram, V.F. Borges, and N. Ibrahim et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer Breast Cancer Res. 11 2009 R73
17. N.K. Ibrahim, K.O. Yariz, and I. Bondarenko et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer Clin. Cancer Res. 17 2011 6822 6830
18. J.L. Gulley, P.M. Arlen, and K.-Y. Tsang et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma Clin. Cancer Res. 14 2008 3060 3069
19. M. Mohebtash, K.-Y. Tsang, and R.A. Madan et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer Clin. Cancer Res. 17 2011 7164 7173
20. D. Raina, R. Ahmad, and M.D. Joshi et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells Cancer Res. 69 2009 5133 5141
21. Y. Zhou, H. Rajabi, and D. Kufe Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors Mol. Pharmacol. 79 2011 886 893
22. M.D. Joshi, R. Ahmad, L. Yin, and D MUC1 oncoprotein is a druggable target in human prostate cancer cells Mol. Cancer Ther. 8 2009 3056 3065
23. M. Ohta, A. Ishida, and M. Toda et al. Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9 Biochem. Biophys. Res. Commun. 402 2010 663 669
24. Y. Ikehara, S.K. Ikehara, and J.C. Paulson Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9 J. Biol. Chem. 279 2004 43117 43125
25. T. Avril, H. Floyd, and F. Lopez et al. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells J. Immunol. 173 2004 6841 6849
26. S. Tanida, K. Akita, and A. Ishida et al. Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth J. Biol. Chem. 288 2013 31842 31852
27. H. Niwa, K. Yamamura, and J. Miyazaki Efficient selection for high-expression transfectants with a novel eukaryotic vector Gene 108 1991 193 199
28. H. Towbin, T. Staehelin, and J. Gordon Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications Proc. Natl. Acad. Sci. U.S.A. 76 1979 4350 4354
29. H. Yurugi, S. Tanida, and K. Akita et al. Prohibitins function as endogenous ligands for Siglec-9 and negatively regulate TCR signaling upon ligation Biochem. Biophys. Res. Commun. 434 2013 376 381
30. B. Agrawal, M.J. Krantz, and M.A. Reddish et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 Nat. Med. 4 1998 43 49
31. C.D. Gimmi, B.W. Morrison, and B.A. Mainprice et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells Nat. Med. 2 1996 1367 1370